SCHEMBL304020

SCHEMBL304020

CCOC(=O)c1cccc(-n2ncc3c(N)cccc32)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
NPBWR1 P48145 1/20 0.53
MCHR1 Q99705 1/20 0.53
ESRRA P11474 1/20 0.52
CDC25B P30305 2/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
TSHR P16473 1/20 0.49
ALOX15 P16050 1/20 0.48
ATM Q13315 1/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
ELANE P08246 1/20 0.46
CCR1 P32246 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303757 0.86 CCR1 (0.55) ESRRAALDH1A1HPGDATMLMNA
SCHEMBL4789419 0.85 HTT (0.49) HTTNPBWR1MCHR1ESRRAALDH1A1
SCHEMBL4789418 0.81 HTT (0.49) HTTNPBWR1MCHR1ESRRAALDH1A1
SCHEMBL8043565 0.80 HTT (0.68) HTTNPBWR1MCHR1ALDH1A1HPGD
SCHEMBL14454774 0.79 NPBWR1 (0.53) HTTNPBWR1MCHR1ESRRAALDH1A1
SCHEMBL303719 0.79 TDP1 (0.45) HTTALDH1A1HPGDSMN1; SMN2ALOX15
SCHEMBL8046909 0.78 KMT2A (0.61) HTTNPBWR1MCHR1ALDH1A1HPGD
SCHEMBL1775488 0.78 NR3C1 (0.48) ESRRAALDH1A1HPGDMAPTRXFP1
SCHEMBL9609077 0.78 NR3C1 (0.46) HTTNPBWR1MCHR1RXFP1CCR1
SCHEMBL4295664 0.77 KMT2A (0.56) HTTNPBWR1MCHR1ESRRAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
EP-1869003-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-26 EP disclosed
WO-2006108699-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, MC2R HTT 3474/4885NPBWR1 263/4885MCHR1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.